3.91MMarket Cap-208P/E (TTM)
3.0900High2.9300Low13.07KVolume2.9900Open2.9000Pre Close39.29KTurnover1.28%Turnover RatioLossP/E (Static)1.27MShares17.400052wk High0.22P/B3.17MFloat Cap2.870052wk Low--Dividend TTM1.02MShs Float170.0000Historical High--Div YieldTTM5.52%Amplitude2.8700Historical Low3.0050Avg Price1Lot Size
Pasithea Therapeutics Stock Forum
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
54 seconds ago, 4:02 AM PST
Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule --
-- No dose-limiting toxicities (DLTs) observed to date --
-- No rash observed to date --
📊⚡️📊
Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules
No comment yet